Outlook Therapeutics Revenue and Competitors

Location

#7438

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Outlook Therapeutics's estimated annual revenue is currently $3.9M per year.(i)
  • Outlook Therapeutics's estimated revenue per employee is $77,500
  • Outlook Therapeutics's total funding is $52M.

Employee Data

  • Outlook Therapeutics has 50 Employees.(i)
  • Outlook Therapeutics grew their employee count by 9% last year.

Outlook Therapeutics's People

NameTitleEmail/Phone
1
VP- Head QualityReveal Email/Phone
2
Head Information Technology DepartmentReveal Email/Phone
3
SVP, Commercial OperationsReveal Email/Phone
4
VP Sales Operations, Data, and AnalyticsReveal Email/Phone
5
SVP, Clinical & Regulatory AffairsReveal Email/Phone
6
ControllerReveal Email/Phone
7
SVP, Medical AffairsReveal Email/Phone
8
SVPReveal Email/Phone
9
SVP, Head EuropeReveal Email/Phone
10
Director Financial Planning and AnalysisReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$10.1M655%N/AN/A
#10
$16.1M1049%N/AN/A
Add Company

What Is Outlook Therapeutics?

Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex, technically challenging and commercially attractive monoclonal antibody, or mAb, for various ophthalmic indications. Our goal is to launch ONS-5010 as the first, and only, approved bevacizumab in the United States, Europe, Japan and other markets for the treatment of wet age related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). ONS-5010 is an innovative mAb therapeutic currently enrolling patients in a clinical trial outside the United States designed to serve as the first of two adequate and well controlled studies evaluating ONS-5010 for wet AMD. We plan to submit an investigational new drug, or IND, application with the U.S. Food and Drug Administration, or FDA, in the first quarter of calendar 2019 and the U.S. portion of the second study is scheduled to begin at that time. Our ONS-5010 wet AMD clinical program was reviewed at a successful end of Phase 2 meeting with the FDA conducted in 2018. If the program is successful, it will support our plans to submit for regulatory approval in multiple markets in 2020. Because there are no approved bevacizumab products for the treatment of retinal diseases, we are developing ONS-5010 as an innovative therapy and not using the biosimilar drug development pathway.

keywords:N/A

$52M

Total Funding

50

Number of Employees

$3.9M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Outlook Therapeutics News

2022-04-19 - BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics

Outlook Therapeutics, Inc. Fri, April 22, 2022, 5:05 AM ·4 min read. In this article: OTLK. Outlook Therapeutics, Inc. SINGAPORE and ISELIN, N.J., April 22,...

2022-04-06 - Outlook Therapeutics to Present at Wet AMD and DME Drug ...

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg), an investigational...

2022-03-30 - Outlook Therapeutics Submits Biologics License Application to the ...

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg), an investigational...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.7M5138%N/A
#2
$6.8M52N/AN/A
#3
$7.2M554%N/A
#4
$5M556%N/A
#5
$8.7M56N/AN/A